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Abstract
The renal function is a key-issue in HIV/HCV co-infected patients, nevertheless, it has not
established so far whether HCV treatment with new direct acting agents could impact on
estimated glomerular filtration rate (eGFR) variations. In the present work, we examined the
real-life data on renal function that have been prospectively collected in the SIMIT
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compassionate-use program of ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r
+ DSV) in 144 HIV/HCV genotype 1 co-infected patients. The population was 74% male,
30.5% in CDC stage C, with median age of 52 years (48.0–56.5) and median liver stiffness
of 7.8 kPa (6.7–9.2). Median baseline eGFR was 102.0 (90.8–108.1), changing to 99.8
(83.5–104.8) at the end of treatment (EoT), and 100.0 (87.3–105.6) 12 weeks after the EoT
(FU12), p<0.0001. No patient had grade 3–4 increase of creatinine. At EoT 60/144 (41.7%)
patients had 5% reduction in their eGFR, confirmed at FU12 in 39/60 (65.0%) cases. Lon-
ger duration of HCV infection (cut-off 12.9 years), lower HCV-RNA viral load (cut-off
1,970,160 IU/ml) and lower platelet count (cut-off 167,000 x106/L) were significantly associ-
ated with eGFR decline at logistic analysis (adjOR 2.9, 95%CI 1.0–8.8, p = 0.05; adjOR 3.5,
95%CI 1.2–10.4, p = 0.02; adjOR 2.8, 95%CI 1.1–6.8, p = 0.03, respectively). After repeating
the analysis throughout a mixed model, a higher eGFR decline was highlighted in patients
concomitantly treated with tenofovir (p = 0.0001), ribavirin (p = 0.0001), or integrase inhibi-
tors (p <0.0001), with longer duration of HIV (p = 0.0002) and HCV infection (p = 0.035),
lower baseline HCV RNA (p <0.0001), previous HCV treatment (p<0.0001), and older age
(p<0.0001). In conclusion, our study confirms a good renal safety profile of OBV/PTV/r +
DSV treatment in HIV/HCV patients, and the median decline of 2 ml/min in eGFR, albeit sta-
tistically significant, is of doubtful clinical significance. The role of aging, concomitant thera-
pies and duration of HIV/HCV infection needs to be further investigated.
Introduction
New direct-acting antiviral (DAA) agents have radically changed the therapeutic scenario of
chronic HCV infection in both mono-infected and HIV co-infected patients [1, 2]. The
3-DAA regimen of ombitasvir, paritaprevir plus ritonavir, and dasabuvir (OBV/PTV/r + DSV)
has showed high efficacy in clinical trials in HIV/HCV co-infected patients [3, 4] and recent
data on compassionate-use program for OBV/PTV/r + DSV, coordinated by the Italian Society
of Infectious and Tropical Diseases (SIMIT), have confirmed high efficacy in real-life setting
in HCV genotype 1 infected patients [5]. Moreover, good tolerability without major adverse
events attributable to the study drugs has been reported in the same context [5], but an analysis
focalized on the trend of the renal function has not been performed yet. In patients co-infected
with HIV/HCV the renal safety is an issue of primary interest, as HCV and HIV both consti-
tute risk factors for renal disease. HIV infection may be linked to HIV-associated nephropathy
(HIVAN) or favour renal thrombotic microangiopathy, focal segmental glomerulosclerosis
and immunecomplexes deposition in the glomerulus [6]. Moreover, some of the drugs used in
combined antiretroviral therapy (cART) have possible renal side effects or long-term toxicity
[7]. On the same time, HCV infection is linked to a series of immune-mediated glomerulopa-
thies as well as to possible cryoglobulinemia-linked renal vasculitis [8] and hepatorenal syn-
dromes in more advanced stages of liver disease [9]. Nevertheless, little is known on the trend
of estimated glomerular filtration rate (eGFR) in patients who clear HCV infection during and
after treatment with new DAAs, especially in real life settings [10, 11]. A worsening of renal
function after DAA treatment has been reported in patients with cirrhosis, and in those treated
with OBV/PTV/r + DSV [10]. Nevertheless, it has not established so far whether HCV clear-
ance is related or not with an improvement in GFR, or if, on the contrary, the combination of
antiretroviral drugs and DAAs can even cause a reduction of GFR, throughout a direct mecha-
nism or indirectly, for drug-drug interactions (DDI).
eGFR trend during therapy with ombistasvir/paritaprevir/ritonavir plus dasabuvir
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With the aim of analysing the creatinine and eGFR trends in a specific population of HIV/
HCV genotype 1 co-infected individuals treated with the same DAA regimen, we examined
the data on renal function of the population treated in the SIMIT compassionate-use program
of OBV/PTV/r + DSV [5].
Materials and methods
The SIMIT compassionate-use program provided access to treatment for patients co-infected
with HIV and HCV genotype 1 or 4, with or without compensated cirrhosis.
The program enrolled 213 patients at 26 sites. Patients were treated for 12 or 24 weeks
based on the absence or presence of cirrhosis. Ribavirin (RBV) was administered twice daily
according to body weight and label recommendations [12]. Patients receiving a ritonavir-
boosted ART regimen discontinued the ritonavir component of their ART regimen as recom-
mended by the local OBV/PTV/r + DSV label [13, 14].
In this sub-study, the inclusion criteria were: a) Patient is at least 18 years of age, infected
with HIV and with HCV genotype 1 (subgenotype 1a, 1b, other) or 4; b) Patient has compen-
sated cirrhosis (Child Pugh score A) OR liver fibrosisF3 (by Metavir or equivalent assess-
ment including those by an alternative technology such as FibroScan1) and a condition which
contraindicates an IFN based treatment, or clinically significant extra-hepatic manifestation(s)
of HCV infection, or rapidly progressive fibrosis OR Patient has a liver transplant and HCV
Genotype 1 infection and is at least 12 months post liver transplantation, has had a recent
(within 6 months) assessment of liver fibrosis asF2, does not have a diagnosis of fibrosing
cholestatic hepatitis; c) Patients has creatinine levels available at baseline (BL), at the end of
treatment (EoT) and 12 weeks after the end of treatment (FU12). Duration of HIV and HCV
infection was estimated assuming that infection was contracted at June 15th of the year in
which the first positive serologic test was reported. Laboratory data were prospectively col-
lected at BL, EoT, FU12 and 24 weeks after the end of treatment (FU24). GFR was calculated
according to the CKD-EPI equation [15], while the stage of kidney disease was classified
according to KDIGO (Kidney Disease: Improving Global Outcomes) definition [16]. Creati-
nine increase was classified according to tables for grading the severity of adult and pediatric
adverse events of the division of AIDS (DAIDS) [17]. Fibrosis scores were assigned on the
basis of the liver stiffness measured by Fibroscan1, F1 (<7.1 kPa), F2 (7.1–9.6 kPa), F3
(> 9.6–12.5 kPa), F4 (>12.5 kPa) [5]. The complete dataset used to perform the statistical anal-
ysis is available in S1 Table. Quantitative data were presented as medians (1st and 3rd quartile)
and categorical data as absolute numbers and percentages. Some variables (i.e. age, HIV and
HCV duration, BL HCV-RNA) were dichotomized according to the best threshold obtained
from the receiver operating characteristic (ROC) curve analysis [18]. Dichotomization of
explanatory variables has the advantage of providing clinically meaningful odds ratios (ORs)
with 95% confidence intervals (95% CIs). A logistic regression model was used to assess the
impact of baseline characteristics of patients (age, gender, BMI, CDC stage, grade of liver fibro-
sis, BL HCV-RNA, years of HIV and HCV infection, BL CD4+ T-lymphocytes and nadir,
CKD stage), lifestyle habits (smoke, alcohol use), comorbidities (diabetes, hypertension, symp-
tomatic cryoglobulinemia) concomitant treatments in course of OBV/PTV/r + DSV (tenofovir
[TDF] and ribavirin [RBV] use), and previous treatment for HCV, on the reduction of at least
5% in eGFR at both EoT and FU12. The same variables were also studied in a logistic regres-
sion model in the post-hoc analyses, to investigate if they could influence a5% improvement
of eGFR in a subgroup of patients. Factors significant at univariate analysis were added in a
multivariate model after stepwise procedure. A two-way repeated measures mixed model
ANOVA analysis with Tuckey post-test was run to establish if there was a relationship between
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eGFR at follow-up and age, hypertension, stage of fibrosis, TDF, integrase strand transfer
inhibitors (INSTI), protease inhibitors (PI) and RBV use, previous HCV treatment, years of
HCV and HIV infection, CD4+T-lymphocyte nadir and BL HCV-RNA.
The compassionate use of the combination of OBV/PTV/r + DSV was approved on individ-
ual base for each patient (AbbVie1 named-Patient Program). The full list of Ethical Commit-
tees that approved the program is available in S1 File. All patients in the study provided
written informed consent. The study was conducted in accordance with the International
Conference on Harmonization guidelines, applicable regulations, and the principles of the
Declaration of Helsinki.
Results
Among patients included in the SIMIT compassionate-use program, 144 HIV/HCV co-
infected people satisfied inclusion criteria. The population was 74% male (107/144 patients),
with median age of 52 years (48.0–56.5), and median CD4+T-cell count of 658 cells /μl (480–
929).The median CD4+T cell nadir was 190 cells /μl (74–314). All but three (2.1%) patients
had HIV-RNA load<50 copies/ml. According to Centers for Disease Control and Prevention
(CDC) definition, 66 (45.8%) patients were stage A, 44 (30.5%) stage B and 29 (30.5%) stage C.
All patients had documented HCV genotype 1 infection (1a in 94, 1b in 44, 1a/b in five and 1
not further characterized in one). Median liver stiffness was 7.8 kPa (6.7–9.2) at baseline.
Regarding the route of HIV/HCV transmission, the majority of patients (n = 107, 74.3%)
reported previous intravenous drug use, 26 (18.1%) unprotected sexual intercourse (5.6%
homo/bi-sexual and 12.5% eterosexual), five (3.4%) transfusions of blood components, while
in the remaining seven (4.9%) it was unknown. Three patients had more than one risk factor:
two patients with previous intravenous drug use and one with previous transfusions of blood
components, that also reported unprotected sexual intercourse. Demographic and clinic char-
acteristics of the study population are summarized in Table 1.
The eGFR was available for all 144 patients at BL, at the EoT and at FU12, according to inclu-
sion criteria, while 73/144 (50.7%) patients also had an available follow-up at FU24. Median BL
eGFR was 102.0 (90.8–108.1), changing to 99.8 (83.5–104.8) at the EoT, and 100.0 (87.3–105.6)
at FU12 (p<0.0001). No patient had grade 3–4 increase of creatinine. The maximum increase
of creatinine levels during treatment was 0.35 mg/dl. At the EoT 60/144 (41.7%) patients
had 5% reduction in their GFR, confirmed at FU12 in 39/60 (65.0%) cases. FU24 was avail-
able for 30/60 (50%). Of them, 15/30 (50%) had confirmed eGFR decline 5% also at FU24.
For 39 patients with confirmed eGFR decline both at the EoT and FU12, the possible associ-
ation among renal function impairment and other comorbidities (hypertension, diabetes),
TDF, PI, INSTI or RBV use, as well as baseline characteristics of the patients (age, sex, duration
of HIV and HCV infection, HIV stage, baseline HCV-RNA and platelet count, CD4+ T-cell
nadir and BL CD4+T-cell count, liver stiffness and previous HCV treatment) was investigated
(Table 2).
In a multivariate model including duration of HCV infection (cut-off 12.9 years, dichoto-
mized as per ROC), BL HCV-RNA viral load (cut-off level 1,970,160 IU/ml, dichotomized as
per ROC), and BL platelet count (cut-off level 167,000 platelets x106/L, dichotomized as per
ROC), longer HCV infection and lower HCV-RNA levels were significantly associated with
eGFR decline > 5% (adjOR 2.9, 95%CI 1.0–8.8, p = 0.05, and adjOR 3.5, 95%CI 1.2–10.4,
p = 0.02, respectively), as well as lower platelet count (adjOR 2.8, 95%CI 1.1–6.8, p = 0.03).
The results obtained without the dichotomizations as per ROC of continue variables (age,
BL HCV-RNA, platelet count, transaminases and years of HCV and HIV infection) were also
studied and are presented in S2 Table.
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Table 1. General characteristics of the study population at baseline (BL). Data are expressed as medians (1st - 3rd
quartiles) or absolute frequencies (percentage).
Variable N Median (q1-q3)
Age 144 52 (48.0–56.05)
Years of HCV 119 17.9 (10.9–20.9)
Years of HIV 142 23.9 (16.9–27.9)
BL CD4 143 658 (480–929)
CD4 nadir 133 190 (74–314)
BL HCV-RNA (IU/ml) 144 1,137,573 (517,764.5–3,041,840)
BL HIV-RNA (copies/ml) 144 0.0 (0.0–0.0)
BL AST (IU/L) 142 48.5 (34–77.5)
BL ALT (IU/L) 143 64 (41–99.5)
BL PLT (x106/L) 143 179,000 (145,000–266,500)
Variable N n (%)
Female 144 37 (25.69)
Caucasian 144 144 (100.00)
Experienced to HCV treatment 142 65 (45.77)
BMI 134
<20 16 (11.94)
20–25 75 (55.97)
>25 43 (32.09)
CDC stage 139
A 66 (47.48)
B 44 (31.65)
C 29 (20.86)
CKD stage 144
1 111 (77.08)
2 30 (20.83)
3 3 (2.08)
HCV Genotype 144
1a 94 (65.28)
1b 44 (30.55)
1 a/b 5 (3.47)
1 (unknown) 1 (0.69)
RISK FACTOR 144
IVDU 106 (73.6)
Homosexual/ bisexual 8 (5.56)
Heterosexual 18 (12.5)
Hemotransfusion 5 (3.47)
Other/unknown 7 (4.86)
HABITS AND COMORBIDITIES
Smoking 132 76 (57.58)
Alcool use 140 48 (34.29)
Diabetes 144 14 (9.72)
Hypertension 144 34 (23.61)
Symptomatic Cryoglobulinemia 144 11 (7.64)
CONCOMITANT THERAPIES 144
cART 143 (99.31)
RBV 115 (79.86)
(Continued)
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To account for possible differences into restricted subgroups of patients, differences among
eGFR values were also estimated at all available time-points, including FU24, for all 144
patients throughout a mixed model (Table 3).
In particular, patients on concomitant treatment with TDF or RBV were at risk for signifi-
cant eGFR decline compared to people who were not (p = 0.0001 and p = 0.0001, respectively)
in the time between BL and EoT, but the difference was not confirmed when comparing BL to
FU12 and FU24, nor between values of these time-points compared in pairs. A significant
eGFR decline between BL and EoT was also found in patients with at least one of the following
characteristics: age> 45 years (p<0.0001), previous HCV treatment (p<0.0001), longer dura-
tion of HIV and HCV infections (p = 0.0002 for more than 16.9 years of HIV infection and
p = 0.035 for more than 12.9 years of HCV infection), lower baseline HCV-RNA (p<0.0001
for HCVRNA values 1,970,160 IU/ml), treatment with an INSTI (<0.0001) and not on a PI-
containing cART (<0.0001). A longer duration of HIV infection (p = 0.0034), an older age
(p = 0.0324), a lower baseline HCV RNA (p = 0.001), INSTI use (p = 0.031) and not being on
PI-based cART (p = 0.024) were associated with a significant decrease in eGFR levels in the
time between BL and FU12. A longer duration of HIV infection and INSTI use also main-
tained correlation with a decrease of the eGFR at FU24 (Table 3). The trend of eGFR according
to baseline CKD stage is shown in Fig 1. In order to clarify if there was a sub-group of patients
who improved their eGFR, a post-hoc analysis was also performed. Overall, 14 patients had
confirmed eGFR improvement of 5% at both EoT and FU12. The logistic analysis revealed
that the improvement was more probable in CKD stage 2 and 3 when compared to CKD stage
1 (Odds Ratio, OR, 9.7, 95%CI 2.7–35.2, p = 0.0005 and OR 53.5, 95%CI 4.0–720.1, p = 0.003,
respectively), while no significant correlation was found with other factors.
Discussion
This study analyses the eGFR trend in a large and homogeneous cohort of patients with HIV/
HCV genotype 1 co-infection and mild fibrosis prospectively treated with OBV/PTV/r + DSV.
The main findings is that no patient experienced grade 3–4 increase of creatinine levels
throughout HCV treatment and FU, and the finding of a median decline of 2 ml/min in eGFR,
albeit statistically significant, was of doubtful clinical significance.
Previous trials evidenced the good safety profile and efficacy (higher than 90%) of OBV/
PTV/r + DSV among patients with stage IV or V CKD [19]. A very few cases (2/179 patients)
of creatinine clearance decrease to<50 ml/min (in a single determination) have been reported
in PEARL II study, (3/419 patients, all in treatment with ribavirine) in PEARL III and (3/305
patients, 1 who was in treatment with RBV, and 2 who were not) in PEARL IV [20–22]. Mehta
Table 1. (Continued)
Variable N Median (q1-q3)
TDF 111 (77.08)
INSTI 110 (76.39)
PI 38 (26.39)
N = number of patients for which data was available; n = absolute number of patients with each variable; % =
percentage of patients with the specific variable, calculated as n/N; q1 = first quartile; q3 = third quartile;
AST = aspartate aminotransferase; ALT = alanine aminotransferase; PLT = platelets; IVDU = intravenous drug use;
BMI = body mass index; CKD chronic kidney disease; cART = combined antiretroviral therapy; RBV = ribavirin;
TDF = tenofovir; INSTI = integrase inhibitors; PI = protease inhibitors.
https://doi.org/10.1371/journal.pone.0192627.t001
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et al. [23] have recently analysed the eGFR trend in HCV mono-infected patients treated with
OBV/PTV/r + DSV in phase 3 trials SAPPHIRE I/ II, TOPAZ I /II, and RUBY I /II. In this
comprehensive analysis, they found a change in eGFR of + 0.39 ml/min in patients enrolled in
SAPPHIRE I/II trials (n = 776 patients), with significant improvement in the subgroup of
patients with CKD stage 2 and 3. On the other hand, in TOPAZ I/II (n = 2206 patients) and in
RUBY I/II trials (n = 78 patients), the overall eGFR decreased, with a significant negative trend
(p<0.001) in patients in CKD stage 1 enrolled in TOPAZ I/II trials. Similarly, in our study, we
found HIV/HCV co-infected patients had a significant decrease of the eGFR, driven by the
high prevalence of CKD stage 1, while, in patients in CKD stages 2 and 3, the eGFR improved.
In other trials and registration studies of other DAAs, on-treatment assessments included the
evaluations of renal function, but specific analyses on the trend of creatinine clearance have
not been performed [22–34]. Some studies had arisen more specifically the issue of renal safety
using different criteria for CKD classification and progression as, at present, the evaluation of
renal function in course of DAA therapy has not been standardized so far. As a consequence,
some studies have reported the numbers of abnormal creatinine rises of any grade [35], while
Table 2. Univariate and multivariate predictors of event (eGFR decline> 5%) in the study population (144 patients).
OR (95% CI)
univariate
p-value adjOR (95%CI) multivariate p-value
Age >45 years 3.0 (0.8–10.7) 0.09
Gender (Male) 1.2 (0.5–2.9) 0.66
Smoke 0.7 (0.3–1.6) 0.46
Alcohol 1.2 (0.6–2.7) 0.59
Diabetes 1.6 (0.5–5.0) 0.45
Hypertension 1.4 (0.6–3.2) 0.43
Symptomatic cryoglobulinemia 1.0 (0.2–4.0) 0.99
CDC stage B vs. A 1.4 (0.6–3.1) 0.44
CDC stage C vs. A 0.7 (0.2–2.0) 0.50
Grade of liver fibrosis F2 vs. F1 0.5 (0.1–2.2) 0.33
Grade of liver fibrosis F3 vs. F1 0.8 (0.2–4.4) 0.83
RBV use 1.6 (0.6–3.7) 0.32
TDF use 1 (0.4–2.4) 0.98
PI use 0.4 (0.2–1.1) 0.07
INSTI use 2.6 (0.9–7.3) 0.07
PreviousHCV treatment 0.6 (0.3–1.2) 0.12
BMI (<20) vs. (20–25) 0.7 (0.2–2.4) 0.58
BMI 2 (>25) vs. (20–25) 0.5 (0.2–1.2) 0.12
Years of HCV> 12.9 3.1 (1.1–8.8) 0.03 2.9 (1.0–8.8) 0.05
Years of HIV> 16.9 2.3 (0.9–5.9) 0.10
CKD stage 2 vs. 1 0.8 (0.3–2.0) 0.61
CKD stage 3 vs. 1 1.3 (0.1–14.7) 0.84
Baseline CD4< = 350 0.2 (0.3–1.8) 0.16
CD4 Nadir < 100 cells/μl 1.3 (0.6–2.9) 0.48
BL HCV RNA< = 1,970,160 3.4 (1.3–8.8) 0.01 3.5 (1.2–10.4) 0.02
PLT < = 167,000 4.1 (1.9–8.8) 0.0004 2.8 (1.1–6.8) 0.03
TDF: tenofovir; RBV: ribavirin; PI: protease inhibitors; INSTI: integrase strand transfer inhibitors; PLT: platelets; OR: odds ratio; adjOR: adjusted odds ratio; CI:
confidence interval.
Dichotomized as per ROC
https://doi.org/10.1371/journal.pone.0192627.t002
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Table 3. Number of patients tested throughout mixed models and correlation with eGFR decline at different time-points.
Variable n correlation with GFR decline (adjusted p)
from BL toEoT from BL toFU12 from BL to FU24
TDF Y 111 0.0001 0.119 0.078
N 33 0.408 0.686 0.970
RBV Y 115 0.0005 0.151 0.067
N 29 0.117 0.536 0.998
PI Y 38 0.994 0.994 1.000
N 106 <0.0001 0.024 0.016
INSTI Y 110 <0.0001 0.031 0.046
N 34 0.918 0.991 0.999
Age >45 years Y 120 0.0001 0.032 0.1096
N 24 0.4645 0.9969 0.9854
Hypertension Y 34 0.9961 0.9126 0.9564
N 110 <0.0001 0.0595 0.0984
Metavir stage of fibrosis F1 117 0.0028 0.0407 0.4627
F2 17 0.6405 1.0000 0.9996
F3 8 0.2521 0.9996 0.1427
Experienced to HCV treatment Y 65 <0.0001 0.2631 0.0739
N 77 0.2198 0.343 0.8492
HCV since >12.9 years Y 80 0.0035 0.094 0.1861
N 39 0.3615 1.0000 0.9961
HIV since >16.9 years Y 106 0.0002 0.0034 0.0319
N 36 0,3547 1.0000 0.9998
Nadir CD4>100 cells/μL Y 90 0.0035 0.2951 0.5598
N 43 0.0082 0.0813 0.2733
BL HCV-RNA< = 1,970,160 IU/ml Y 98 <0.0001 0.001 0.0879
N 46 0.9723 1.0000 0.9739
GFR: glomerular filtration rate; n: number of patients; Y: yes; N: no; BL: baseline; EoT: end of treatment; FU12: 12 weeks after the end of treatment; FU24: 24 weeks after
the end of treatment; TDF: tenofovir; RBV: ribavirin.
Dichotomized as per ROC. Metavir stage of fibrosis is given according to stiffness evaluation by Fibroscan1
https://doi.org/10.1371/journal.pone.0192627.t003
Fig 1. Trend of estimated glomerular filtration rate (eGFR) in the global population, according to GITMO renal
stage at baseline (BL). n = number of patients in each chronic kidney disease (CKD) stage. EoT: End of treatment;
FU12: follow-up 12 weeks after the EoT; FU24: follow-up 24 weeks after the EoT.
https://doi.org/10.1371/journal.pone.0192627.g001
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others only those of grade 3–4 [36–38], using different scaling systems. Additionally, the num-
ber of patients with an increase in creatinine levels of 0.4 mg/dl or more during treatment has
also been used [36,37], or the change in mean creatinine clearance through week 12 [37, 39]. In
the general population, the age-related decline in eGFR is generally believed to be less than 1
ml/min each year, i.e. about 1% of eGFR, assuming a filtration rate of 100 ml/min [40], while, in
HIV infected patients, a rapid eGFR decline is usually defined by a reduction in eGFR5 ml/
min/year in patients with baseline eGFR> 90 ml/min [41]. This corresponds to about 5%
decline in patients with normal eGFR (CKD stage 1), while, in patients with baseline eGFR<90
ml/min, a 5% decline permits to take into account also lower absolute changes in eGFR.
We chose to use a decline of eGFR of5% within 12 weeks, i.e. 5-fold higher than what
expected in one year period, as a marker of abnormal renal function decline.
Of note, we did not found any creatinine rise of grade >2 or of0.4 ml/min and the
reported median decline of 2 ml/min in eGFR, even if statistically significant, has doubtful
clinical significance. In fact, current guidelines recommend to refer to a nephrologist in case of
eGFR decline by> 25% or to a level< 60 ml/min [42]. Moreover, we cannot exclude that this
slight decline could be followed by a late improvement, as previously found in liver transplant
recipients with mild chronic kidney disease that achieved SVR after interferon-based regimens
[43].
Another remarkable finding of our study is that a5% eGFR decline was related to a longer
history of HCV infection and to lower baseline HCV-RNA and platelet count. The correlation
with duration of HCV infection could be expected, as, even if the linkage between HCV and
CKD is controversial, many evidences underline a possible correlation. In the veteran cohort,
HCV infection was found not to have a relation with progressive CKD [44], but, in other large
cohorts, both HCV viremic and HCV aviremic individuals were found at increased risk for
moderate and advanced CKD compared with HIV-infected subjects who were HCV seronega-
tive [45] and HCV co-infection was found as an independent risk factor for CKD in HIV [46].
On the contrary, the higher probability of eGFR decline in patients with lower BL HCV-RNA
was unexpected, and is in contrast with the evidence of higher Odds Ratios for CKD that have
been found in patients with higher HCV-RNA [46, 47]. A previous paper on 1,676 HIV/HCV
co-infected patients treated for HCV, revealed an incidence of CKD of 5.32 per 1000 person/
years of follow-up, without significant differences between patients who achieved sustained
virologic response (SVR) and those who not, suggesting a possible minor role for the current
viremia on the development of renal injury [48]. On the other hand, higher risks of CKD have
been found in patients with detectable HCV RNA than in those who cleared the infection [49]
and a higher HCV-RNA has been demonstrated an independent predictor of CKD [50]. We
think that these evidences, all together, underline a major role of the global burden of the HCV
disease, that is correlated to high HCV-RNA and to years of HCV infection. In the same direc-
tion also goes the association between eGFR decrease and lower platelet count, that might sug-
gest a higher probability of renal injury in more advanced stages of HCV disease. Indeed,
HCV-RNA is fluctuating and the punctual value at the time of study entry might not represent
the real burden of HCV disease in the study population. Another unexpected finding of our
study was that the classical risk factors for kidney disease, such as increasing age, male gender,
history of smoking, diabetes, and hypertension, had no correlation with impairment of renal
function, although it is possible that the effect of such factors could not be appreciable in a rela-
tively young population with low prevalence of diabetes and hypertension.
We also tested eGFR trend within the groups for each measure period, through a mixed
model for multiple comparisons that permitted to consider also the interaction between the
variables and the time. The results confirmed a role of the longer duration of HCV infection
and lower BL HCV-RNA, but also revealed other potential risk factors linked to significant
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eGFR decline, i.e. TDF, INSTI or RBV use, age> 45 years, previous HCV treatment (mainly
IFN-based), and longer duration of HIV infection. Indeed, TDF and IFN are drugs with recog-
nized potential nephrotoxicity, which has also been hypothesized for RBV [51–53] while the
effect of INSTI on possible creatinine increase, driven by both dolutegravir and, to a lesser
extent, raltegravir [54–55], might have had a role in patients who switched to INSTI to avoid
drug interactions during DAA treatment. Moreover, HIV infection and ageing have potential
influence on renal function [56]. However, although these results may be of great interest, they
must be interpreted with caution, because a significant trend toward reduction was seen in the
general population in correlation with time (and in particular between BL and EoT), and it is
possible that it is confirmed in any group big enough to allow a reliable analysis. For the same
reason, the lack of significance in eGFR decline in patients treated with PI and in those with a
history of hypertension do not allow to interpret these factors as protective, but should be
rather interpreted as a non-significance, probably due to small number of patients.
This study has several limitations. The lack of a control group constitutes a major limit of
this study, as we could not compare the eGFR trend of the study population with that of HIV/
HCV co-infected people not undergoing HCV treatment, nor with that of patients treated with
other DAA regimens, including those that are now the preferred first-line agents for HCV treat-
ment [57–58]. Moreover, we had no available urinalysis for the study population, and it limits
the accuracy of a precise diagnosis of renal injury. Also, we did not have complete data about
potentially nephrotoxic concomitant therapies, other than the cART, that could also have played
a role, and FU24 was not available for a large part of the study population, so that the possibility
of a recovery 24 weeks after the EoT was not adequately investigated. Lastly, we dichotomized
the continues variables included in the regression model, as binary covariates offer a simple risk
classification into high versus low and, in the regression setting, the interpretation of the impact
of a binary covariate on outcome is easier than that for a change of 1 unit in a continuous covar-
iate [59]. However, this approach could have influenced the significance of some results, as it
can sometimes lead to biased estimates in regression settings. When categorizing continuous
covariates, there is always the possibility of loss of information, possible loss of power to detect
actual significance, and possibility of false positive results as well, and using two groups conceals
any non-linearity in the relation between the variable and outcome [60].
Despite these limitations, we found that the eGFR decline was significant during HCV
treatment, but the same was not found prolonging observation to FU12 in the majority of
groups examined through the mixed models. This could lead us to speculate that a temporary
nephrotoxicity is possible in course of therapy, but, at least in part, reversible. Low baseline
HCV-RNA seems not to be protective in our series, while duration of HCV infection and low
platelet count are risk factors for>5% eGFR decline, independently from chronological age.
On the contrary, patients with poor renal function at the beginning of treatment had higher
probability of renal improvement, even if numbers are too low to draw conclusions.
In summary, our study confirms a good renal safety profile of OBV/PTV/r + DSV treatment
in a large homogeneous cohort of HIV/HCV patients. The role of aging, concomitant therapy
with TDF, INSTI or RBV, previous HCV treatment and duration of HIV infection need to be
further investigated, and studies on larger populations and with longer follow-up are desirable
to better clarify the dynamics of renal function in the contest of DAA treatment.
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